Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial.

J, Xu; A, Wang; X, Meng; G, Yalkun; A, Xu; Z, Gao; H, Chen; Y, Ji; J, Xu; D, Geng; R, Zhu; B, Liu; A, Dong; H, Mu; Z, Lu; S, Li; H, Zheng; X, Chen; Y, Wang; X, Zhao; Y, Wang

doi:10.1161/strokeaha.120.031197

Public

Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial.

Shared by NobleBlocks on Feb 16, 2021 • 12:00 AM UTC

Authors:

Xu J

Wang A

Meng X

Abstract

Background and purpose Edaravone dexborneol, comprised of 2 active ingredients, edaravone and (+)-borneol, has been developed as a novel neuroprotective agent with synergistic effects of antioxidant and anti-inflammatory in animal models. The present clinical trial aimed at testing the effects of ed...

Subject

Antioxidants

neuroprotective agents

Ischemic stroke

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!